Navigation Links
Progress in tissue engineering to repair joint damage in osteoarthritis
Date:6/8/2011

Medical scientists now have "clear" evidence that the damaged cartilage tissue in osteoarthritis and other painful joint disorders can be encouraged to regrow and regenerate, and are developing tissue engineering technology that could help millions of patients with those disorders. That's the conclusion of a new analysis of almost 100 scientific studies on the topic, published in ACS's journal Molecular Pharmaceutics.

Tong Cao, Wei Seong Toh and colleagues point out that damage to so-called articular cartilage the smooth, white, rubbery tissue that covers and cushions the ends of bones in joints is one of the most challenging problems in medicine. That's because the tissue lacks blood vessels and has little ability to repair itself and regrow. Wear-and-tear damage thus builds up over the years, resulting in conditions like osteoarthritis, which affects 27 million people in the United States alone. Osteoarthritis is a fast-growing public health problem because of the world's aging population and because of a sharp increase in obesity, which increases wear on joint cartilage. To assess progress toward medical use of tissue engineering to treat joint damage, the researchers scanned global research on the topic.

They found that scientists have developed many new tissue engineering methods, including implantation of so-called "scaffolds" made of biomaterials that mimic cartilage matrix in the body. The scaffolds could guide the transplanted cells, orchestrate the host cell response, provide structures and microenvironment substances to help rebuild cartilage at the injury site. "In summary, there is promise in future research involving the development of multi-functional biomaterial delivery systems that affect cartilage tissue regeneration on multiple levels," the article states.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Chesapeake Bay programs 2-year milestones improve upon past strategies, but accounting of progress remains a challenge
2. GOLFIG increased progression-free survival in colorectal cancer patients
3. Progress toward the clinical application of autologous induced pluripotent stem cells and gene repair therapy for treatment of familial hypercholesterolemia
4. Older and stronger: Progressive resistance training can build muscle, increase strength as we age
5. Researchers find drug that stops progression of Parkinsons disease in mice
6. Neiker-Tecnalia makes progress in detection and prevention of infection by visna maedi virus
7. Researchers learn why PSA levels reflect prostate cancer progression
8. Progress toward treating infections by silencing microbes smart phones
9. Progress toward first commercial repellent for East Coasts stinker
10. Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
11. Gene-environmental interactions and MS progression is focus of new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... technologies, today announced that it has signed agreements with ... and the Middle East for ... marks the first wave of international distribution agreements for ... blood samples. The initial partners will introduce ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
(Date:1/23/2017)... 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... New Zealand based Phase 1 trial ... remarkable results in reducing inflamed protein biomarkers in patients ... is believed that this is the first time in ... can be made between epigenetic regulation and its potential ...
(Date:1/23/2017)... ... 2017 , ... AxioMed will be presenting its viscoelastic cervical ... Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the benefits ... the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... to bring to market a pioneering medical device for the treatment of Age-Related ... engagement contract with Emergo, a global regulatory consultancy that helps companies like ours ...
Breaking Biology Technology: